RBOT
Vicarious Surgical Inc.
NYSE · Healthcare · Medical - Devices · US
$0.04
−17.23%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +34.2%
- EBIT
- +35.5%
- EPS
- +35.4%
- Free cash flow
- +16.3%
- Operating cash flow
- +16.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +65.6%
- EPS
- +62.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- +20.2%
- EBIT
- +23.4%
- Net income
- +20.6%
- EPS
- +21.2%
- Free cash flow
- +9.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026